Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Common Equity: 2020-2025

Historic Common Equity for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $158.1 million.

  • Arcutis Biotherapeutics' Common Equity rose 0.91% to $158.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.1 million, marking a year-over-year increase of 0.91%. This contributed to the annual value of $157.5 million for FY2024, which is 77.68% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Common Equity is $158.1 million, which was up 13.74% from $139.0 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Common Equity ranged from a high of $451.0 million in Q1 2021 and a low of $46.7 million during Q3 2023.
  • In the last 3 years, Arcutis Biotherapeutics' Common Equity had a median value of $142.7 million in 2025 and averaged $138.3 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Common Equity plummeted by 82.75% in 2023 and then spiked by 235.30% in 2024.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Common Equity stood at $297.7 million in 2021, then fell by 29.59% to $209.6 million in 2022, then tumbled by 57.69% to $88.7 million in 2023, then surged by 77.68% to $157.5 million in 2024, then rose by 0.91% to $158.1 million in 2025.
  • Its last three reported values are $158.1 million in Q3 2025, $139.0 million for Q2 2025, and $142.7 million during Q1 2025.